Bolt Biotherapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Bolt Biotherapeutics, Inc. on June 12, 2024. The filing details the results of votes on director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 15, 2024), 38,127,740 shares were entitled to vote, with 25,928,185 shares represented at the meeting. The following outcomes were reported:
- Director Elections (Class III):
- Kathleen LaPorte: Elected with 12,706,287 votes for, 3,990,176 votes withheld, and 9,231,722 broker non-votes.
- Nicole Onetto, M.D.: Elected with 12,819,050 votes for, 3,880,294 votes withheld, and 9,228,841 broker non-votes.
- Accounting Firm Ratification: PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024.
- Votes For: 23,736,566
- Votes Against: 2,032,686
- Votes Abstaining: 158,933
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class III directors (Kathleen LaPorte and Nicole Onetto, M.D.) through the 2027 Annual Meeting.
- Confirm the high volume of broker non-votes (over 9 million shares) regarding the director elections.
- Note the significant number of votes against the ratification of PricewaterhouseCoopers LLP (over 2 million votes).
- Review the definitive proxy statement filed on April 26, 2024, for detailed background on the proposals.